Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops antibiotics to treat bacterial infections in the United States. Its lead antibiotic candidate, ibezapolstat, has a novel mechanism of action targeting the polymerase IIIC enzyme and is in Phase 2b clinical trials for patients with Clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment for gram-positive bacteria, including MRSA, VRE, and drug-resistant Streptococcus pneumoniae, as well as B. anthracis. Incorporated in 2017, Acurx Pharmaceuticals is headquartered in Staten Island, New York.